<?xml version="1.0" encoding="UTF-8"?>
<results title="drugs">
 <result pre="a newly emerging antiviral mechanism of nucleoside analogs. nucleoside analog" exact="gemcitabine" post="antiviral drugs innate immunity interferon-stimulated gene nucleos(t)ide synthesis 1."/>
 <result pre="nucleoside analog drugs targeting specific viral polymerases (acyclovir for herpesviruses," exact="zidovudine" post="for human immunodeficiency virus (HIV), and sofosbuvir for hepatitis"/>
 <result pre="(acyclovir for herpesviruses, zidovudine for human immunodeficiency virus (HIV), and" exact="sofosbuvir" post="for hepatitis C virus (HCV)) have been successful in"/>
 <result pre="IFN-α [6]. Importantly, extensive studies on the antiviral action of" exact="ribavirin" post="have established the underlying molecular framework of nucleoside analogs."/>
 <result pre="report [1]. In the present review, we focus more on" exact="gemcitabine" post="as a nucleoside analog, which is clinically relevant and"/>
 <result pre="cancers [11,12]. However, in recent years, the antiviral activity of" exact="gemcitabine" post="has also been reported against a broad range of"/>
 <result pre="(IAV), HIV, and enteroviruses (EV) [13,14,15,16,17,18]. The antiviral activities of" exact="gemcitabine" post="against the abovementioned viruses are summarized in Table 1."/>
 <result pre="290 FDA-approved drugs in virus-infected Vero E6 cells and identified" exact="gemcitabine" post="as one of drugs with antiviral activity against both"/>
 <result pre="of 1.2 μM and 4.9 μM, respectively) [13]. More recently," exact="gemcitabine" post="was shown to effectively suppress ZIKV infection and replication"/>
 <result pre="research and development into possible treatments. Effective antiviral activities of" exact="gemcitabine" post="were also found for the replication of HCV in"/>
 <result pre="therapy [20]. In the case of HIV, the combination of" exact="gemcitabine" post="with decitabine, another nucleoside analog in clinical use for"/>
 <result pre="study, Clouser et al. further reported the antiviral effect of" exact="gemcitabine" post="against HIV-related retrovirus, murine leukemia virus (MuLV), in vitro"/>
 <result pre="in murine AIDS model [17]. A significant antiviral effect of" exact="gemcitabine" post="on IAVs was also reported for RPE cells by"/>
 <result pre="al. (EC50 of 0.068 μM) [16]. They also tested whether" exact="gemcitabine" post="had an antiviral effect on several other viruses of"/>
 <result pre="virus (MeV), and vaccinia virus [16]. The antiviral effect of" exact="gemcitabine" post="on EVs, initially performed on Coxsackievirus B3 (CVB3), was"/>
 <result pre="respectively). In the case of HRV, the antiviral effect of" exact="gemcitabine" post="was further confirmed in a virus-infected mouse model [22]."/>
 <result pre="virus-infected mouse model [22]. In this study, intranasal administration of" exact="gemcitabine" post="significantly lowered the pulmonary viral load and inflammation by"/>
 <result pre="lung infiltrating lymphocytes. More recently, Zhang et al. also identified" exact="gemcitabine" post="as the best anti-PV inhibitor from a screen of"/>
 <result pre="[15]. As previously mentioned, accumulating evidence has definitively demonstrated that" exact="gemcitabine" post="is an effective broad-spectrum inhibitor of RNA viruses and"/>
 <result pre="treatment of various virus-associated diseases. Moreover, it is possible that" exact="gemcitabine" post="is effective for other untested RNA viruses. Because gemcitabine"/>
 <result pre="that gemcitabine is effective for other untested RNA viruses. Because" exact="gemcitabine" post="is a deoxycytidine analog that interferes with DNA as"/>
 <result pre="virus classified into the Herpesviridae family, was strongly affected by" exact="gemcitabine" post="[16]. Most of the abovementioned viruses have, at best,"/>
 <result pre="their early stages of infection. In this regard, repurposing of" exact="gemcitabine" post="for the treatment of patients infected with these deadly"/>
 <result pre="is an option to treat patients with a combination of" exact="gemcitabine" post="with other antiviral agents. In this manner, an effective"/>
 <result pre="used clinically. As an example, the synergistic antiviral effect of" exact="gemcitabine" post="in combination with ribavirin, an antiviral drug currently being"/>
 <result pre="CVB3 and EV71 [18]. As previously mentioned, the combination of" exact="gemcitabine" post="with decitabine synergistically suppressed HIV infectivity both in vitro"/>
 <result pre="EV71 [18]. As previously mentioned, the combination of gemcitabine with" exact="decitabine" post="synergistically suppressed HIV infectivity both in vitro and in"/>
 <result pre="vitro and in vivo [17,21]. However, the actual use of" exact="gemcitabine" post="in virus-infected patients necessitates prior in vivo animal studies"/>
 <result pre="studies, two recent studies have reported the antiviral effects of" exact="gemcitabine" post="in murine models [17,22]. More extensive analyses of gemcitabine"/>
 <result pre="of gemcitabine in murine models [17,22]. More extensive analyses of" exact="gemcitabine" post="in animal models in the near future will accelerate"/>
 <result pre="Pyrimidine Biosynthesis Inhibitors Most studies regarding the antiviral activity of" exact="gemcitabine" post="lack experimental evidence of the mode of action. However,"/>
 <result pre="mode of action. However, our group has recently reported that" exact="gemcitabine" post="had an anti-EV effect by targeting the salvage pathway"/>
 <result pre="by targeting the salvage pathway of pyrimidine biosynthesis [23]. Moreover," exact="gemcitabine" post="strongly induced the expression of several ISGs including CXCL10,"/>
 <result pre="infection. These results were consistent with a previous report that" exact="gemcitabine" post="stimulated the production of IFN-β and IFN-γ in IAV-infected"/>
 <result pre="as summarized in Table 2 [6,10,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42]. Regarding purine biosynthesis inhibitors," exact="ribavirin" post="and mycophenolic acid (MPA) are inhibitors of inosine-5′-monophosphate (IMP)"/>
 <result pre="in Table 2 [6,10,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42]. Regarding purine biosynthesis inhibitors, ribavirin and" exact="mycophenolic acid" post="(MPA) are inhibitors of inosine-5′-monophosphate (IMP) dehydrogenase (IMPDH), which"/>
 <result pre="the stimulation of ISGs [10,30]. For the antiviral activity of" exact="ribavirin" post="against HCV, ribavirin specifically induced the expression of IRF7,"/>
 <result pre="ISGs [10,30]. For the antiviral activity of ribavirin against HCV," exact="ribavirin" post="specifically induced the expression of IRF7, IRF9, and ISG15"/>
 <result pre="classical JAK/STAT system, which is similar to that observed with" exact="ribavirin" post="[30]. Similar results were obtained with several IMPDH1 or"/>
 <result pre="was not mediated by JAK [10]. Second, IRF7 induction by" exact="ribavirin" post="was not affected by knockdown of STAT1, while that"/>
 <result pre="under the same conditions [6]. Third, our recent study with" exact="gemcitabine" post="further confirmed IFN signal-independent ISG activation by parallel studies"/>
 <result pre="signal-independent ISG activation by parallel studies comparing the effects of" exact="gemcitabine" post="and IFN-α. In our study, the phosphorylation of STAT1"/>
 <result pre="dramatically triggered by IFN-α, did not occur when treated with" exact="gemcitabine" post="[23]. Moreover, the upregulation of DDX58 mRNAs induced by"/>
 <result pre="gemcitabine [23]. Moreover, the upregulation of DDX58 mRNAs induced by" exact="gemcitabine" post="was not affected by IRF9 knockdown, which was contrary"/>
 <result pre="classical IFN signal in the activation of ISGs induced by" exact="ribavirin" post="[6]. Despite the consensus of ISG activation, each purine/pyrimidine"/>
 <result pre="than one signaling pathway involved. The synergistic antiviral activity of" exact="gemcitabine" post="and ribavirin observed in our study might be explained"/>
 <result pre="signaling pathway involved. The synergistic antiviral activity of gemcitabine and" exact="ribavirin" post="observed in our study might be explained by the"/>
 <result pre="encephalitisN. Eng. J. Med.198631414414910.1056/NEJM1986011631403033001520 4.KahnJ.O.LagakosS.W.RichmanD.D.CrossA.PettinelliC.LiouS.H.BrownM.VolberdingP.A.CrumpackerC.S.BeallG.et al.A controlled trial comparing continued" exact="zidovudine" post="with didanosine in human immunodeficiency virus infection. The niaid"/>
 <result pre="J. Med.198631414414910.1056/NEJM1986011631403033001520 4.KahnJ.O.LagakosS.W.RichmanD.D.CrossA.PettinelliC.LiouS.H.BrownM.VolberdingP.A.CrumpackerC.S.BeallG.et al.A controlled trial comparing continued zidovudine with" exact="didanosine" post="in human immunodeficiency virus infection. The niaid aids clinical"/>
 <result pre="virus cell culture modelsHepatology201153324110.1002/hep.2398521254160 7.LeyssenP.BalzariniJ.de ClercqE.NeytsJ.The predominant mechanism by which" exact="ribavirin" post="exerts its antiviral activity in vitro against flaviviruses and"/>
 <result pre="virus replicationAntimicrob. Agents Chemother.2016602834284810.1128/AAC.02700-1526926637 11.HertelL.W.BoderG.B.KroinJ.S.RinzelS.M.PooreG.A.ToddG.C.GrindeyG.B.Evaluation of the antitumor activity of" exact="gemcitabine" post="(2′,2′-difluoro-2′-deoxycytidine)Cancer Res.199050441744222364394 12.CerqueiraN.M.FernandesP.A.RamosM.J.Understanding ribonucleotide reductase inactivation by gemcitabineChemistry2007138507851510.1002/chem.20070026017636467 13.DyallJ.ColemanC.M.HartB.J.VenkataramanT.HolbrookM.R.KindrachukJ.JohnsonR.F.OlingerG.G.Jr.JahrlingP.B.LaidlawM.et"/>
 <result pre="respiratory syndrome coronavirus infectionAntimicrob. Agents Chemother.2014584885489310.1128/AAC.03036-1424841273 14.KuivanenS.BespalovM.M.NandaniaJ.IanevskiA.VelagapudiV.de BrabanderJ.K.KainovD.E.VapalahtiO.Obatoclax, saliphenylhalamide and" exact="gemcitabine" post="inhibit zika virus infection in vitro and differentially affect"/>
 <result pre="and metabolismAntivir. Res.201713911712810.1016/j.antiviral.2016.12.02228049006 15.ZhangZ.YangE.HuC.ChengH.ChenC.Y.HuangD.WangR.ZhaoY.RongL.VignuzziM.et al.Cell-based high-throughput screening assay identifies 2′,2′-difluoro-2′-deoxycytidine" exact="gemcitabine" post="as a potential antipoliovirus agentACS Infect. Dis.20173455310.1021/acsinfecdis.6b0011627733043 16.DenisovaO.V.KakkolaL.FengL.StenmanJ.NagarajA.LampeJ.YadavB.AittokallioT.KaukinenP.AholaT.et al.Obatoclax,"/>
 <result pre="a potential antipoliovirus agentACS Infect. Dis.20173455310.1021/acsinfecdis.6b0011627733043 16.DenisovaO.V.KakkolaL.FengL.StenmanJ.NagarajA.LampeJ.YadavB.AittokallioT.KaukinenP.AholaT.et al.Obatoclax, saliphenylhalamide, and" exact="gemcitabine" post="inhibit influenza a virus infectionJ. Biol. Chem.2012287353243533210.1074/jbc.M112.39214222910914 17.ClouserC.L.HoltzC.M.MullettM.CrankshawD.L.BriggsJ.E.O’SullivanM.G.PattersonS.E.ManskyL.M.Activity of"/>
 <result pre="Biol. Chem.2012287353243533210.1074/jbc.M112.39214222910914 17.ClouserC.L.HoltzC.M.MullettM.CrankshawD.L.BriggsJ.E.O’SullivanM.G.PattersonS.E.ManskyL.M.Activity of a novel combined antiretroviral therapy of" exact="gemcitabine" post="and decitabine in a mouse model for HIV-1Antimicrob. Agents"/>
 <result pre="17.ClouserC.L.HoltzC.M.MullettM.CrankshawD.L.BriggsJ.E.O’SullivanM.G.PattersonS.E.ManskyL.M.Activity of a novel combined antiretroviral therapy of gemcitabine and" exact="decitabine" post="in a mouse model for HIV-1Antimicrob. Agents Chemother.2012561942194810.1128/AAC.06161-1122271861 18.KangH.KimC.KimD.E.SongJ.H.ChoiM.ChoiK.KangM.LeeK.KimH.S.ShinJ.S.et"/>
 <result pre="model for HIV-1Antimicrob. Agents Chemother.2012561942194810.1128/AAC.06161-1122271861 18.KangH.KimC.KimD.E.SongJ.H.ChoiM.ChoiK.KangM.LeeK.KimH.S.ShinJ.S.et al.Synergistic antiviral activity of" exact="gemcitabine" post="and ribavirin against enterovirusesAntivir. Res.201512411010.1016/j.antiviral.2015.10.01126526589 19.BeranR.K.SharmaR.CorsaA.C.TianY.GoldeJ.LundgaardG.DelaneyW.E.t.ZhongW.GreensteinA.E.Cellular growth kinetics distinguish"/>
 <result pre="HIV-1Antimicrob. Agents Chemother.2012561942194810.1128/AAC.06161-1122271861 18.KangH.KimC.KimD.E.SongJ.H.ChoiM.ChoiK.KangM.LeeK.KimH.S.ShinJ.S.et al.Synergistic antiviral activity of gemcitabine and" exact="ribavirin" post="against enterovirusesAntivir. Res.201512411010.1016/j.antiviral.2015.10.01126526589 19.BeranR.K.SharmaR.CorsaA.C.TianY.GoldeJ.LundgaardG.DelaneyW.E.t.ZhongW.GreensteinA.E.Cellular growth kinetics distinguish a cyclophilin"/>
 <result pre="of a novel HIV combination therapyJ. Virol.2010849301930910.1128/JVI.01006-1020610712 22.SongJ.H.KimS.R.HeoE.Y.LeeJ.Y.KimD.E.ChoS.ChangS.Y.YoonB.I.SeongJ.KoH.J.Antiviral activity of" exact="gemcitabine" post="against human rhinovirus in vitro and in vivoAntivir. Res.201714561310.1016/j.antiviral.2017.07.00328705625"/>
 <result pre="cultured mammalian cellsAntivir. Res.2011891810.1016/j.antiviral.2010.10.00921070810 27.TakhampunyaR.UbolS.HoungH.S.CameronC.E.PadmanabhanR.Inhibition of dengue virus replication by" exact="mycophenolic acid" post="and ribavirinJ. Gen. Virol.2006871947195210.1099/vir.0.81655-016760396 28.YingC.ColonnoR.de ClercqE.NeytsJ.Ribavirin and mycophenolic acid"/>
 <result pre="by mycophenolic acid and ribavirinJ. Gen. Virol.2006871947195210.1099/vir.0.81655-016760396 28.YingC.ColonnoR.de ClercqE.NeytsJ.Ribavirin and" exact="mycophenolic acid" post="markedly potentiate the anti-hepatitis B virus activity of entecavirAntivir."/>
 <result pre="activity of entecavirAntivir. Res.20077319219610.1016/j.antiviral.2006.10.00317098296 29.WangY.ZhouX.DebingY.ChenK.van der LaanL.J.NeytsJ.JanssenH.L.MetselaarH.J.PeppelenboschM.P.PanQ.Calcineurin inhibitors stimulate and" exact="mycophenolic acid" post="inhibits replication of hepatitis E virusGastroenterology20141461775178310.1053/j.gastro.2014.02.03624582714 30.PanQ.de RuiterP.E.MetselaarH.J.KwekkeboomJ.de JongeJ.TilanusH.W.JanssenH.L.van"/>
 <result pre="in vitro and in vivoHepatology2012551673168310.1002/hep.2556222213147 31.PanattoniA.D’AnnaF.TrioloE.Antiviral activity of tiazofurin and" exact="mycophenolic acid" post="against grapevine leafroll-associated virus 3 in vitis vinifera explantsAntivir."/>
 <result pre="vitis vinifera explantsAntivir. Res.20077320621110.1016/j.antiviral.2006.10.00717125850 32.ShirakiK.IshibashiM.OkunoT.KokadoY.TakaharaS.YamanishiK.SonodaT.TakahashiM.Effects of cyclosporine, azathioprine, mizoribine, and" exact="prednisolone" post="on replication of human cytomegalovirusTransplant. Proc.199022168216852167528 33.FurutaY.TakahashiK.FukudaY.KunoM.KamiyamaT.KozakiK.NomuraN.EgawaH.MinamiS.WatanabeY.et al.In vitro"/>
 <result pre="cultureAntimicrob. Agents Chemother.2010543686369510.1128/AAC.00561-1020606073 35.SchlapferE.FischerM.OttP.SpeckR.F.Anti-HIV-1 activity of leflunomide: A comparison with" exact="mycophenolic acid" post="and hydroxyureaAIDS2003171613162010.1097/00002030-200307250-0000512853743 36.FarasatiN.A.ShapiroR.VatsA.RandhawaP.Effect of leflunomide and cidofovir on replication"/>
 <result pre="leflunomide: A comparison with mycophenolic acid and hydroxyureaAIDS2003171613162010.1097/00002030-200307250-0000512853743 36.FarasatiN.A.ShapiroR.VatsA.RandhawaP.Effect of" exact="leflunomide" post="and cidofovir on replication of BK virus in an"/>
 <result pre="comparison with mycophenolic acid and hydroxyureaAIDS2003171613162010.1097/00002030-200307250-0000512853743 36.FarasatiN.A.ShapiroR.VatsA.RandhawaP.Effect of leflunomide and" exact="cidofovir" post="on replication of BK virus in an in vitro"/>
</results>
